Advertisement
Research Article

Efficacy and Safety of Artemether in the Treatment of Chronic Fascioliasis in Egypt: Exploratory Phase-2 Trials

  • Jennifer Keiser mail,

    jennifer.keiser@unibas.ch

    Affiliations: Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland, University of Basel, Basel, Switzerland

    X
  • Hanan Sayed,

    Affiliation: Public Health Department, Theodor Bilharz Research Institute, Giza, Egypt

    X
  • Maged El-Ghanam,

    Affiliation: Hepatogastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt

    X
  • Hoda Sabry,

    Affiliation: Parasitology Department, Theodor Bilharz Research Institute, Giza, Egypt

    X
  • Saad Anani,

    Affiliation: Ministry of Health and Population, Alexandria Governorate, Alexandria, Egypt

    X
  • Aly El-Wakeel,

    Affiliation: Ministry of Health and Population, Behera Governorate, Behera, Egypt

    X
  • Christoph Hatz,

    Affiliations: University of Basel, Basel, Switzerland, Department of Medical Services and Diagnostic, Swiss Tropical and Public Health Institute, Basel, Switzerland, Institute for Social and Preventive Medicine, University of Zurich, Zurich, Switzerland

    X
  • Jürg Utzinger,

    Affiliations: University of Basel, Basel, Switzerland, Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland

    X
  • Sayed Seif el-Din,

    Affiliation: Pharmacology Department, Theodor Bilharz Research Institute, Giza, Egypt

    X
  • Walaa El-Maadawy,

    Affiliation: Pharmacology Department, Theodor Bilharz Research Institute, Giza, Egypt

    X
  • Sanaa Botros

    Affiliation: Pharmacology Department, Theodor Bilharz Research Institute, Giza, Egypt

    X
  • Published: September 06, 2011
  • DOI: 10.1371/journal.pntd.0001285

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.